For US Healthcare Professionals Only
For US Healthcare Professionals Only
At IncyteCARES, our mission is to help eligible patients access their prescribed Incyte medication and to offer information and resources that provide extra support during treatment. Our team is available to patients and their caregivers by phone every weekday.
A completed IncyteCARES for Jakafi Program Enrollment Form can also serve as your patient’s first prescription. Completion takes about 15 minutes.
Reimbursement Support
Savings and Financial Assistance
Education and Resources
For all enrolled patients, we provide:Connection to Other Support
Our team can share information about independent organizations that may offer:To Submit Via Fax
Your Incyte representative can also provide a tear pad of IncyteCARES for Jakafi enrollment forms.
Via Secure Website
There’s no need to set up an account or password. For security, information you enter in the online form is not saved when you close it.
*Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE, or any state medical or pharmaceutical assistance program. Annual benefit maximum applies, as may other restrictions. Valid prescription for Jakafi® (ruxolitinib) for an FDA-approved indication or compendia-recognized use is required. Please see full Patient Terms and Conditions or call IncyteCARES for Jakafi at 1-855-452-52341-855-452-5234. Update effective as of January 1, 2024.
†Free product is offered to eligible patients without any purchase contingency or other obligation. Terms and conditions apply. Terms of these programs may change at any time.
Contact IncyteCARES for Jakafi
Our team is available Monday through Friday, 8 AM to 8 PM ET.
Call us at 1-855-452-5234
MPN=myeloproliferative neoplasm.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.